AlphaGrep UK Ltd’s Guardant Health GH Stock Holding History

AlphaGrep UK Ltd’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$259K	Buy	2,800 +693	+33%	+$69.6K	0.07%	584
2025 Q4	$215K	Buy	+2,107	New	+$188K	0.07%	598

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaGrep UK Ltd's GH Position: Q1 2026 in Review

AlphaGrep UK Ltd increased its Guardant Health (GH) stake by 33% in Q1 2026, buying an estimated $69.6K and bringing the position to 2,800 shares worth $259K. The position accounts for 0.07% of the portfolio, ranked #584.

AlphaGrep UK Ltd first reported a position in GH in Q4 2025 and has held it in 2 quarters since. 484 funds tracked by Wall St. Rank hold GH as of Q1 2026.

AlphaGrep UK Ltd held 2,800 shares of Guardant Health worth $259K as of Q1 2026.
AlphaGrep UK Ltd bought 693 Guardant Health shares in Q1 2026, an estimated $69.6K.
Guardant Health made up 0.07% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #584 holding.
AlphaGrep UK Ltd first reported a position in Guardant Health in Q4 2025 and has held it in 2 quarters since.
484 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.